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Colorectal cancer (CRC) is the second leading cause of cancer
deaths in the United States among cancers that affect both men
and women (1). In 2016, the most recent year for which data are
available, more than 141,000 new cases of CRC were reported,
and more than 52,000 people died of the disease (1). The public
health impact of CRC due to years of potential life lost, the eco-
nomic burden of lost productivity, and the costs associated with
illness  and  treatment  are  substantial.  In  2015,  an  estimated
766,000 person-years of life lost and $9.4 billion in lost earnings
were attributed to CRC deaths, second only to lung cancer (2).
Strong evidence indicates that screening can decrease CRC incid-
ence and mortality  by identifying and removing precancerous
polyps and by detecting CRC early when treatment is more effect-
ive (3). If CRC is detected early, the 5-year survival rate (90%) is
much higher than when it is detected late (14%) (1).
The US Preventive Services Task Force (USPSTF) recommends
CRC screening for average-risk people aged 50 to 75 by fecal oc-
cult blood test (FOBT), fecal immunochemical test (FIT), a com-
bination stool DNA and FIT test (FIT–DNA), computed tomo-
graphic colonography (CTC, or virtual colonoscopy), flexible sig-
moidoscopy, or colonoscopy (3). Despite strong evidence for its
effectiveness, too few eligible adults are screened for CRC. In
2016, 67% of adults aged 50 to 75 reported that they were up-to-
date with CRC screening, whereas 26%, or approximately 22 mil-
lion adults, reported that they had never been screened (4). Screen-
ing rates are lower among people who have a low annual house-
hold income, have no health insurance, have no regular health care
provider, identify as a racial or ethnic minority, or have low levels
of educational attainment (5).
The high public health burden of CRC indicates a need for popula-
tion-level interventions to improve its prevention and control (2).
Although large health systems have implemented programs and
initiatives to improve the quality of CRC screening and treatment
in their populations, coordinated, population-level public health
efforts that reach most, or all, of the US population to address the
burden of CRC have been limited (6). Examples of national or
multistate efforts to increase CRC screening include programs or
campaigns implemented by organizations such as the Centers for
Disease Control and Prevention (CDC) and the American Cancer
Society (ACS). CDC’s Screen for Life: National Colorectal Can-
cer Action Campaign is a national mass media and small media
campaign that  informs adults  about  the  importance  of  getting
screened for CRC (7). In 2014, the National Colorectal Cancer
Roundtable, an organization founded by CDC and ACS to bring
organizations together to coordinate efforts to address the burden
of CRC, launched the 80% by 2018 campaign, which asked organ-
izations of all types to pledge resources toward interventions to in-
crease CRC screening rates (8). More than 1,500 organizations
signed the pledge to participate (9).  From 2013 through 2016,
ACS implemented the Community Health Advocates Implement-
ing Nationwide Grants for Empowerment and Equity (CHANGE)
program, which funded primary care systems, faith-based organiz-
ations, and community-based organizations that partnered with
federally qualified health centers to implement evidence-based in-
terventions to increase breast and CRC screening with technical
assistance from ACS field staff members (10). Finally, CDC’s Na-
tional Comprehensive Cancer Control Program supports the devel-
opment and implementation of cancer control plans, and partners
with state, tribal, and territorial cancer coalitions to leverage re-
sources to address cancer prevention and control, including ef-
forts to increase use of CRC screening tests (11). Literature de-
scribing program design, implementation, or evaluation of these
efforts is limited, suggesting the need for additional information
about best practices to design, implement, and evaluate national or
multistate efforts to increase CRC screening (6,8,10,11).
A collection of 5 articles published in 2019 in Preventing Chronic
Disease describes the evaluation of CDC’s 2009–2015 Colorectal
Cancer Control Program (CRCCP), including its implementation,
outcomes, and costs. These articles contribute to the limited body
of  peer-reviewed  literature  about  programmatic  design  ap-
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proaches and best practices for large, multistate, population-level
public health interventions to increase use of CRC screening tests.
Program Overview
In 2004, CDC funded 5 sites to implement the Colorectal Cancer
Screening Demonstration Program to assess the feasibility of pub-
lic health approaches to address the burden of CRC and the low
uptake of CRC screening tests among populations that tradition-
ally have had limited access to health care services (12).  This
demonstration program was modeled after the long-standing Na-
tional  Breast  and  Cervical  Cancer  Early  Detection  Program
(NBCCEDP), authorized by Congress to provide breast and cer-
vical cancer screening and diagnostic services to low-income, un-
insured, and underinsured women. The NBCCEDP demonstrated
success in working with provider networks, community partners,
professional organizations, and other partners to provide access to
high-quality cancer screening and diagnostic services. On the basis
of the success of the Colorectal Cancer Screening Demonstration
Program and lessons learned from both the demonstration pro-
gram  and  the  NBCCEDP,  in  2009  CDC  launched  the  5-year
CRCCP to provide CRC screening tests to low-income, uninsured,
and underinsured populations and to promote the importance of
screening with the ambitious goal of increasing screening rates to
80%.
Through a competitive application process, CDC funded 22 states
and 4 tribal organizations to implement the CRCCP. In July 2010,
CDC funded an additional 3 states, bringing the total number of
grantees to 29 (13). The CRCCP comprised 2 program compon-
ents: 1) screening provision, which provided CRC screening tests
for people with low incomes and no or limited health insurance,
and 2) screening promotion, which involved activities to increase
awareness and uptake of CRC screening on a population level.
For the screening provision component, grantees used a portion of
their awards to fund clinical screening services. Grantees estab-
lished contracts with health care providers to deliver screening to
the priority population: asymptomatic people aged 50 to 64 who
had an annual household income less than or equal to 250% of the
federal poverty level and were uninsured or underinsured for CRC
screening services. “Underinsured” was defined in various ways
across grantees, but in general it referred to people who did not
have insurance coverage for preventive services (eg, they had cata-
strophic health care coverage only) or could not afford copays or
deductibles. People aged 65 or older were excluded from receiv-
ing these screening services because they were covered by Medi-
care. Grantees had the option to fund any CRC screening test in-
dicated in the 2008 USPSTF recommendations (FOBT, FIT, flex-
ible sigmoidoscopy, or colonoscopy). Additional program activit-
ies to support screening included patient outreach and awareness,
patient navigation, provider education, quality assurance, and data
management.
For the screening promotion component, grantees implemented
evidence-based interventions (EBIs) identified in The Community
Guide (14) to increase population-level use of CRC screening. At
the time of program initiation, EBIs included client and provider
reminders, provider assessment and feedback, reduction of struc-
tural barriers, and small media (15).
Evaluation Design
CDC undertook an evaluation of the CRCCP to assess implement-
ation, outcomes, and costs. Grantees also conducted local evalu-
ations. CDC designed its evaluation on the basis of CDC’s Frame-
work for Program Evaluation (16) and identified these goals:
Describe how CRCCP grantees implement the program.•
Assess changes in key outcomes, including population-level CRC screening
prevalence.
•
Describe the costs of implementing the CRCCP for both screening provision
and screening promotion.
•
Three unique data  collection methods  were  used.  To evaluate
screening provision, a patient-level data set was developed (CRC
clinical data elements, or CCDEs). To assess implementation of
EBIs, CDC conducted an annual grantee survey, and to assess
cost, grantees completed a cost assessment tool (Table).
CRCCP Evaluation Findings
In this collection, 5 articles address aspects of 4 evaluation ques-
tions: 1) Is complete and timely screening delivered, and what are
the screening outcomes? 2) What strategies are grantees imple-
menting? 3) Are state-level colorectal cancer screening rates in-
creasing? and 4) What is the cost of delivering the CRCCP? Nadal
et al assessed the quality of screening services provided through
the screening provision component of the program (17). On the
basis of accepted standard practices, they analyzed CCDE data
collected by CDC on the timing and results of all screening and
diagnostic  tests  provided  and  the  quality  of  colonoscopies
provided. Researchers found that most positive results for FOBTs
and FITs were appropriately followed up with colonoscopy to
complete the screening process, and most of the colonoscopies
were completed within the time frame of 180 days recommended
by CDC. Additionally, the authors found that most colonoscopies
performed met national quality standards. Although most quality
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indicators were met by grantees, quality varied substantially across
grantees. The article discusses the challenges of modifying the be-
haviors of health care providers to improve the quality of services
provided.
Hannon et al analyzed data from grantee surveys to examine use
of EBIs and facilitators and barriers to implementation (18). The
authors found that most grantees implemented and maintained cli-
ent-oriented  EBIs  such  as  client  reminders  and  small  media.
Grantees considered these EBIs easier to implement than provider-
oriented EBIs or reduction of structural barriers. Unexpectedly,
implementation of EBIs did not become easier over time, possibly
because of the need to build and sustain partnerships over time
with health care providers and organizations.
Three articles evaluated the cost of delivering the CRCCP. Hoover
et al described the development of a web-based cost-assessment
tool to collect cost data and evaluate the quality of the data collec-
ted by the tool (19). The authors found that most grantees were
able to use the tool to allocate at least 95% of the funds they re-
ceived to program activities. Keys to successful implementation of
the tool were solicitation of grantee input during the development
and design phases and staff members dedicated to providing tech-
nical assistance to grantees. Subramanian et al described the clin-
ical and nonclinical costs of the direct screening services provided
(ie, screening provision) by grantees (20). Although the authors
found that direct clinical costs were higher for colonoscopy-only
screening programs than for FOBT/FIT-only programs, nonclinic-
al costs did not vary by screening test type, suggesting that these
programs have substantial fixed costs. Finally, Tangka et al ex-
amined differences in grantees’ expenditures for screening promo-
tion (21). Researchers found that grantees allocated nearly one-
third of their funding to screening promotion activities that had in-
sufficient evidence of effectiveness (eg, mass media) as determ-
ined by The Community Guide (14) and smaller amounts were al-
located toward recommended interventions (eg, small media, pro-
vider assessment and feedback, client and provider reminders).
The 2009–2015 CRCCP was the first public health program fo-
cused solely on increasing use of CRC screening tests at the popu-
lation  level  in  multiple  states  by  supporting  both  direct  CRC
screening services and CRC promotion through implementation of
EBIs. The findings from the articles in this collection provide im-
portant information that can inform future programs of the type
and scope of the CRCCP. First, although grantees were successful
in providing high-quality screening services directly to more than
50,000 people who had limited or no health insurance, the cost of
program  infrastructure  was  high,  and  the  number  of  people
screened was much lower than the number of people who were eli-
gible for the program. This finding led CDC to decrease funding
for direct screening services in the current CRCCP (2015–2020)
and focus on implementation of EBIs in primary care clinics to re-
duce program infrastructure costs while potentially increasing pro-
gram reach. Second, we found that most programs did not have
state-wide reach and most were unable to measure changes in up-
take of CRC screening tests by using a population measure such as
the Behavioral Risk Factor Surveillance System. As a result, the
2015–2020 CRCCP requires  grantees  to  partner  directly  with
health systems and primary care clinics that serve populations
known to have low CRC screening test use (eg, federally quali-
fied health centers) to implement EBIs and to report clinic-level
CRC screening data to measure success. This change also allows
grantees to narrow the scope of their programs by focusing on
high-need populations while still potentially expanding their over-
all reach. Third, we found that grantees allocated a disproportion-
ate amount of their awards toward interventions with limited evid-
ence for their effectiveness (eg, mass media), and grantees found
client-oriented interventions, such as client reminders and small
media, easier to implement. The 2015–2020 CRCCP now requires
that grantees choose at least 2 of 4 priority EBIs (client reminders,
provider assessment and feedback, provider reminders, and reduc-
tion of structural barriers) that have sufficient or strong evidence
of effectiveness in increasing CRC screening.  The 2015–2020
CRCCP grantees are strongly encouraged to partner with various
organizations, such as primary care associations, ACS, and entit-
ies with expertise in health information technology, to facilitate
the implementation of both client-oriented and provider-oriented
EBIs in primary care clinics.
The evaluation findings from the 2009–2015 CRCCP were critic-
al  to  inform the design and implementation of  the 2015–2020
CRCCP (22). The usefulness of the findings demonstrates the im-
portance of a well-designed and executed evaluation plan. Al-
though the 2009–2015 CRCCP was unique in its design, size, and
scope,  these  evaluation findings  can be useful  to  other  public
health organizations planning or implementing similar population-
level interventions to increase CRC screening. Program planners
should carefully consider the potential reach and infrastructure
costs of direct CRC screening services given available sources of
funding, the size of the potential target population relative to the
capacity and funding of program implementers, the selection of
EBIs that maximize program effects while minimizing costs, and
the ability of program implementers to leverage the resources of
other public and nonpublic health organizations to facilitate imple-
mentation. Evaluation should be an integral part of program plan-
ning and should answer questions about how the program was im-
plemented and its effectiveness. Evaluation findings from pro-
grams such as the CRCCP are vital to demonstrate the effective-
ness of public health programs in addressing the burden of CRC in
the United States.
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Table
Table. Evaluation Questions and Data Collection for CDC’s 2009–2015 Colorectal Cancer Control Program (CRCCP)
Evaluation Question Data Collection Tool
Reporting
Frequency
Unit of
Measurement Constructs or Variables
Is complete and timely screening
delivered, and what are the screening
outcomes?
Colorectal cancer clinical
data elements (CCDEs)
Semi-annually Patient • Patient demographics
• Dates and results of screening and diagnostic
tests
• Final diagnosis
What strategies are grantees
implementing?
Grantee survey Annually Grantee • Grantee characteristics
• Implementation of evidence-based
interventions
• Partnerships
Are state-level colorectal cancer
screening rates increasing?
Behavioral Risk Factor
Surveillance System
Every 2 years State CRC screening rate
What is the cost of delivering the
CRCCP?
Cost assessment tool Annually Grantee • Costs of screening provision
• Costs of screening promotion
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